



# A resilient approach to modelling the supply and demand of platelets in the United Kingdom Blood supply chain

DOI:

[10.1080/17509653.2021.1892548](https://doi.org/10.1080/17509653.2021.1892548)

## Document Version

Accepted author manuscript

[Link to publication record in Manchester Research Explorer](#)

## Citation for published version (APA):

Ejohwomu, O., Too, J., & Edwards, D. (2021). A resilient approach to modelling the supply and demand of platelets in the United Kingdom Blood supply chain. *International Journal of Management Science and Engineering Management*, 16(2), 143-150. <https://doi.org/10.1080/17509653.2021.1892548>

## Published in:

International Journal of Management Science and Engineering Management

## Citing this paper

Please note that where the full-text provided on Manchester Research Explorer is the Author Accepted Manuscript or Proof version this may differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version.

## General rights

Copyright and moral rights for the publications made accessible in the Research Explorer are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

## Takedown policy

If you believe that this document breaches copyright please refer to the University of Manchester's Takedown Procedures [<http://man.ac.uk/04Y6Bo>] or contact [uml.scholarlycommunications@manchester.ac.uk](mailto:uml.scholarlycommunications@manchester.ac.uk) providing relevant details, so we can investigate your claim.





**A resilient approach to modelling the supply and demand of platelets in the United Kingdom Blood supply chain**

|                  |                                                                               |
|------------------|-------------------------------------------------------------------------------|
| Journal:         | <i>International Journal of Management Science and Engineering Management</i> |
| Manuscript ID    | TMSE-2020-0121.R2                                                             |
| Manuscript Type: | Case Study                                                                    |
| Keywords:        | platelets, simulation, inventory management, optimisation, blood supply chain |
|                  |                                                                               |

SCHOLARONE™  
Manuscripts

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**A resilient approach to modelling the supply and demand of platelets in the United Kingdom Blood supply chain**

For Peer Review Only

## Abstract

The short shelf-life of platelets together with their stochastic demand and variable supply creates problematic decision making for inventory managers who seek to maintain optimal stock levels. This paper develops a novel simulation model that acts as a decision support tool for identifying optimal stock levels that would guarantee the availability of stock and, eliminate wastages and outages within the platelet supply chain. A multi-method approach is delineated upon that combines agent-based and discrete event modelling built on Anylogic software using data collected from typical UK Stock Holding Units (SHUs). The model simulates the demand and supply of 24 different platelet types broken down into their ABO and rhesus groupings and recommends the appropriate stock level at SHUs that will reduce expiries by 78% while simultaneously guaranteeing stock availability. This research not only represents the first attempt to fully understand the UK platelet supply chain but also presents an advanced simulation model that adopts a ‘pull’ system of platelet inventory management. Further, the concept of resiliency is integrated into the design of the solution methodology by testing the model behaviour in unexpected disruptions in the supply chain during an emergency case study.

**Keywords:** *Blood supply chain, platelets, simulation, inventory management, optimisation.*

## 1.0. Introduction

The supply of blood products is irregular (due to the uncertainty of donor willingness) and its demand stochastic (Beliën & Forcé, 2012) making it difficult to accurately forecast production and schedule blood donations (Samani et al., 2020). Therefore, inventory management seeks a trade-off between shortages and wastages to guarantee the availability of blood products while simultaneously minimizing expiries (Stanger, et al., 2012). Although more than a hundred different products can be extracted from blood, platelets, red blood cells and plasma are the most important components (Katsaliaki & Brailsford, 2017). Platelets are particularly significant because they have multiple uses in chemotherapy, bone marrow transplants, treatment of coronary artery diseases and more recently, researchers have discovered its application in developing a Coronavirus (COVID-19) vaccine (Chang et al., 2020).

One challenge for inventory managers, however, is that platelets have the highest rate of perishability- with a short five to seven days storage shelf-life (Zahiri, et al., 2018). Indeed, in the USA and Western Europe, approximately 20% of platelets collected result in expiries (Rajendran & Ravindran, 2020). Apart from wastages, unpredictable challenges caused by unplanned surgeries, natural disasters, equipment breakdown, war and labour strikes lead to significant disruptions and losses within the blood supply chain and consequently, unsatisfied demands (Haeri et al., 2020). It is crucial therefore to public health, that policies are adopted that assimilate the concept of 'resilience' (i.e. an innate ability to withstand large-scale disruptions) into planning and inventory management to remain reliable despite unexpected challenges (Rajendran & Srinivas, 2020).

To resolve this aforementioned problematic public health conundrum and achieve equilibrium between blood products supply and demand, this study focuses on platelet inventory management and seeks to answer the following inductive questions: 1) What is the

1  
2  
3 optimal level of platelet inventory that will meet demand and reduce shortages? 2) What is  
4 the impact of relying on hospital demand to make decisions on inventory levels at Stock  
5 Holding Units (SHUs) vis-à-vis depending on the supply side? 3) How can resilient inventory  
6 management decisions be made in the face of an emergency?  
7  
8  
9  
10

11  
12 Although several authors have attempted to provide a solution to the platelet inventory  
13 management problem, Beliën & Forcé (2012) report upon a discernable lack of fully scalable  
14 models (both mathematical and simulation) that provide clear demonstrable evidence of  
15 performance improvement in practice. Most innovative academic solutions are limited to  
16 theoretical contexts only (Stanger, et al., 2012a) and research into blood inventory  
17 management remains scant (Rajendran & Srinivas, 2020). Within the specific area of platelet  
18 inventory management research, consideration of the different platelet categories, together  
19 with their ABO and rhesus groupings remains unexplored. Studies predominantly devote  
20 their analysis to one type of platelet product (Haeri et al., 2020), which is mostly apheresis  
21 platelets. Furthermore, integrating the concept of resiliency into the design of a solution  
22 methodology for platelet inventory management has not yet been fully addressed. Haeri et al  
23 (2020) conducted perhaps the closest match to this present study and considered different  
24 resiliency measures in the blood supply chain. However, their study (*ibid*) focuses on the  
25 design of the blood supply chain network. Consequently, this current research utilizes data  
26 collected from a real-life SHU in England to develop a pragmatic decision support tool that  
27 can be implemented in generating optimal stock levels. In addition to being the first attempt  
28 to fully understand the UK platelet supply chain, this novel study is also the first to propose a  
29 multi-product simulation model that advances previous simulation models viz.: 1) It analyses  
30 24 different types of platelet categories broken down into apheresis, pooled and paediatric  
31 platelets, the different ABO categories and their rhesus groupings. While previous  
32 researchers have developed bespoke solutions for the blood supply chain, their focus has  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 mainly been on red blood cells and apheresis platelets; 2) The simulation model was designed  
4 to operate based on a ‘pull’ system meaning that the stock levels at the SHU are influenced  
5 by hospital demands. The pull system facilitates elimination of wastage and reduction of cost  
6 (Lu & Zheng, 2009) since the model’s outputs inform production planning; 3) Substitution of  
7 platelet products is considered; 4) The model’s resilience was tested in an emergency case  
8 study of a real-life SHU.  
9

10  
11 The rest of the paper is organised as follows: *section 2.0. The platelet supply chain: a*  
12 **literature review** synthesises relevant literature on platelet supply chain; *section 4.0.*  
13 **Materials and methods** presents the case study; *section 3.0. Case study description*  
14 delineates the methodology utilised in this paper; *section 5.0. Results* presents the study’s  
15 results and managerial insights inferred from these, and *section 6* provides conclusions and  
16 signposts future opportunities for further research.  
17

## 18 **2.0. The platelet supply chain: a literature review**

19  
20 Extant literature on platelet supply chain optimisation reviewed illustrates that international  
21 studies have critically evaluated platelet inventory management optimisation approaches  
22 from various context-specific perspectives. Although early studies extend back to the 1960s  
23 (Cohen & Pierskalla, 1979; Osorio et al., 2015), the platelet supply chain has hitherto  
24 received scant academic attention until recent years (Blake, 2017).  
25

26  
27 Haijema et al. (2009) adopted Stochastic Dynamic Programming (SDP) with simulation to  
28 arrive at policies that they claim would lead to shortage levels of less than 1% and reduce  
29 wastages from 20% to 1% during Christmas, New Year’s and Easter breaks. Due to the short  
30 shelf-life of platelets, these breaks may seriously affect the levels of shortages and wastages;  
31 making their findings particularly noteworthy. Van Dijk et al. (2009) ignored the stock age  
32 distribution and combined SDP with discrete event modelling to arrive at an ‘order-up-to’  
33 rule for each day of the week. The major limitation of this study, however, was their  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

oversight in the presentation of results. Blake (2009) points out this error and strongly contests the results of Van Dijk, et al. (2009), arguing that ignoring the age-distribution of stock yields inventory levels are not practical. Further, Abdulwahab & Wahab (2014) analyzed the performance of the Canadian Blood Service and proposed a mathematical model based on approximate dynamic programming. The model examined different supply policies (circular, first-in-first-out (FIFO) and last-in-first-out (LIFO)), concluding that increasing the order delivery to two times per day and incorporating a strict FIFO policy produces minimal inventory shortages, minimum outdates and minimum average inventory. Katsaliaki & Brailsford (2017) adopted a different approach and utilised discrete-event simulation. They (*ibid*), concluded that strict adherence to FIFO inventory policy and the introduction of two routine deliveries to hospitals (*vis-a-vis* one), would improve the system performance, arriving at the same conclusion as Abdulwahab & Wahab (2014).

The World Health Organization (2011) guidelines recommend that adequate contingency plans should be implemented by blood centres for collection, processing and use of blood products during a pandemic. Rajendran & Srinivas (2020), consider the effects of disruption on the supply chain and adopt mathematical modelling to develop inventory management policies that offer a trade-off between wastages and shortages. Haghjoo et al. (2020); Hosseini-Motlagh et al. (2020); Hamdan & Diabat (2020) and Yaghoubi et al. (2020) made further contributions in developing solutions for optimising the supply chain under disruptions to minimize transportation, inventory and fixed costs as well as lower the rate of shortages and wastages.

### 3.0. Case study description

The National Health Services Blood and Transplant (NHSBT) is mandated to ensure that blood products are delivered to UK hospitals in a timely and sufficient manner. Approximately 28,000 units of blood and its components are collected weekly from fixed and



1  
2  
3 mobile donation centres. The collected blood is then tested for ABO, rhesus grouping,  
4  
5 infectious agents and viruses, and then processed in manufacturing centres (Baesler, et al.,  
6  
7 2014). The three manufacturing centres within the UK (located in Manchester, Colindale and  
8  
9 Bristol) centrifuge whole blood into the three major components: plasma, platelets and red  
10  
11 blood cells. After processing, the blood components are stored in SHUs ready for issue when  
12  
13 ordered by transfusion laboratory managers. The current approach for inventory management  
14  
15 in the SHUs is to hold fixed stock targets that are reviewed every six months. This simplistic  
16  
17 approach to inventory management of platelets tends to be time-consuming and makes it  
18  
19 difficult to make production decisions that will result in optimal inventory levels. Since  
20  
21 evidence-based inventory management is what leads to best practice in blood services, this  
22  
23 study adopted one of the SHUs as a case study to illustrate the applicability of the developed  
24  
25 simulation model and its solution approach for effective platelet inventory management.  
26  
27  
28  
29

#### 30 **4.0. Materials and methods**

31  
32  
33 A mixed philosophical stance was adopted using interpretivism to analyse existing literature  
34  
35 and justify the novelty of this present study (Roberts et al., 2018), and positivism (Edwards et  
36  
37 al., 2020) to develop the simulation model. Within this overarching epistemology, a mixed-  
38  
39 method approach was adopted, incorporating both qualitative and quantitative techniques to  
40  
41 comprehensively model the case study. This approach was implemented in five stages that  
42  
43 were interrelated to each other; specifically, the output of one stage iteratively informing the  
44  
45 next as illustrated in *Figure 1*.  
46  
47  
48

49 >> *Insert Figure 1* <<

#### 50 51 **4.1. Focus group discussions**

52  
53 In this multi-level single case study, a non-probability sampling technique was used to  
54  
55 constitute a focus group. The formation of the group, discussions and site visits to two of the  
56  
57 three manufacturing sites occurred over twenty months; an extended period that was not only  
58  
59  
60

1  
2  
3 needed to negotiate research support but also secure a more comprehensive understanding of  
4 the operational activities of the SHU. This practical knowledge accrued was instrumental in  
5 developing the simulation model that accurately reflected reality. Focus group discussions  
6 were chosen because unlike interviews, they provide a more precise and clearly defined focus  
7 on the topic, enabling an interactive discussion between the participants (Pärn and Edwards,  
8 2017). The focus group participants consisted of six senior staff members of NHSBT who are  
9 responsible for making decisions on the stock levels within the UK blood supply chain and  
10 had between 5 and 30-years' experience in blood manufacturing. Although a sample frame of  
11 ten staff was originally identified as relevant to the study, only six responded positively thus  
12 representing a 60% response rate. Semi-structured questions were used to guide interactions,  
13 and the ensuing discourse recorded, transcribed and analysed using NVivo.

#### 28 **4.2. Developing the simulation model**

30 The simulation model was built on a multi-method approach combining both agent-based and  
31 discrete event modelling. This simulation model allows for the comparison of various  
32 inventory policy alternatives for the 24 different platelet products while supporting decision  
33 making in a stochastic environment by evaluating appropriate stock levels through what-if  
34 analysis (Terzi & Cavalieri, 2004). Due to the complexity of the platelet supply chain,  
35 system behaviour cannot be accurately defined (Osorio et al., 2015). However, the key  
36 variables and dependencies within the system were identified. Agent-based modelling was  
37 chosen since it allows the system's 'global' behaviour to be understood by merging  
38 individual behaviours (Grigoryev, 2018). The variable 'hospital demand' was taken as an  
39 agent interconnected with another agent; the 'SHU' and the activities within the SHU such as  
40 'replenishment orders', 'shortages', and 'wastages' modelled using discrete-event to show  
41 how they interact within the system. The model was developed on Anylogic software  
42 together with a Java code written to replicate the daily transaction activities at the SHU.

1  
2  
3 Overall, the simulation model considers a ‘pull’ system where the stock levels are influenced  
4 by hospital demand (refer to *Figure 2*), eliminating the need to ‘push’ blood products to the  
5  
6 hospitals.  
7  
8

9  
10 >> *Insert Figure 2*<<

#### 11 12 **4.2.1. Data required by the model**

13  
14 Data on hospital demands for the 24 different platelet categories by platelet type, quantity and  
15 blood group were obtained for the period between April 2017 and June 2019. Historical data  
16 was collected over two years to cover any seasonality that brings about variation in demand  
17 thus, presenting an accurate picture of the platelet supply chain. A source of uncertainty in  
18 this model (as replicated in a real system) is hospital demand for platelet units. Therefore, to  
19 incorporate variability in this demand, normal probability distributions at 95% confidence  
20 level were fitted to historical hospital demand data and analysed as input parameters for the  
21 model.  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32

#### 33 **4.2.2. Model assumptions**

34  
35 The simulation was developed based on the following model assumptions: 1) Since the  
36 platelet shelf-life is seven days (Blake, 2017; Zahiri et al., 2018), the model assumes a shelf-  
37 life of four days because processing at the manufacturing centre before the product arrives at  
38 the SHU takes up to three days; 2) A FIFO ordering policy is strictly adhered to at the SHU;  
39  
40 3) The SHU has enough staff and equipment to operate at increased capacity; and 4) Since  
41 the model scope does not extend to the manufacturing and donation centres, it is assumed that  
42 there is enough platelet supply to replenish the SHU’s orders and the lead time is two days.  
43  
44  
45  
46  
47  
48  
49

#### 50 **4.2.3. Model behaviour**

51  
52 The inventory levels of the 24 platelet types were modelled based on a continuous inventory  
53 review system; accounting for fluctuations in stock according to hospital demand and  
54 replenishment orders from the manufacturing centre (refer to *Figure 3*). Given the critical  
55  
56  
57  
58  
59  
60

1  
2  
3 importance of having some blood products on hand (at all times) in the SHU, minimal safety  
4 stock and dynamic re-order points were defined for each platelet product at a 95% service  
5 level. The stock received from the manufacturing centre is stored in FIFO order at the SHU.  
6  
7  
8

9  
10 >> *Insert Figure 3*<<

11  
12 Ideally, a hospital should be supplied with the same blood group of platelets that they have  
13 ordered from the SHU but this is not always possible due to product unavailability.  
14 Therefore, to manage the supply and demand, NHSBT may (in certain situations) request  
15 hospitals to accept a different ABO group from what was ordered. A Negative platelets for  
16 instance are the universal platelet type and are provided as a substitute for hospital demands.  
17 Each hospital request is first matched with the available stock in the SHU and the model  
18 allows for substitution for A Negative platelets if the same group demanded is unavailable at  
19 the time of the request. To reinforce this point, Participant A said:  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

30 *“In basic what I am doing all the time is making more of the more valuable units. Like*  
31 *all the ones that are A Neg, I am just always making more... I am doing a lot of*  
32 *substitution to push all the products out...”*  
33  
34  
35  
36

37 The model runs for a year, which is considered to be sufficient to capture the variability in the  
38 processes at the SHU - taking into consideration that one complete cycle of a platelet unit is  
39 only seven days.  
40  
41  
42  
43  
44

#### 45 **4.3. Model verification and validation**

46  
47 The model was developed over four iterations based on feedback from professional  
48 practitioners in the UK blood supply chain. It was first built based on the authors'  
49 understanding of the platelet supply chain and thereafter modified to include ageing of the  
50 platelet units over four days, A Negative platelet substitution and incorporating a dynamic re-  
51 order point for each of the products. The model was verified as a true representation of the  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 daily transactions at the SHU and its assumptions also viewed to be reasonable and realistic –  
4  
5 as indicated by participant E viz:

6  
7  
8 *“ The assumptions are sensible for the SHUs.”*  
9

10 The model was populated with data from operations in the SHU in 2019 and was validated  
11  
12 for reasonableness of its outputs by running the simulation 100 times. Harrell et al. (1995)  
13  
14 highlight that this number of replications is ideal for ascertaining model output accuracy. The  
15  
16 validation results showed no significant difference in the operational inventory and wastage  
17  
18 levels (refer to *Table 1*).  
19

20  
21  
22 >> *Insert Table 1* <<

## 23 24 **5.0. Results**

25  
26 The daily inventory levels derived from the simulation were compared to the actual target  
27  
28 stock held at the SHU for July 2019 (specifically 1<sup>st</sup> July to 28<sup>th</sup> July 2019) and the variance  
29  
30 determined as overstocked units. Due to the short shelf-life of platelets, this study describes  
31  
32 an overstocked unit as any surplus platelet unit held within the SHU that is nearing expiry as  
33  
34 confirmed by participant A, viz:

35  
36  
37 *“I mean if a platelet is near day 7, it is an overstock as I am very unlikely to use it,*  
38  
39 *I’m pretty sure I’m gonna expire it, I have zero probability to use it”*  
40  
41

42 Since the level of inventory held at the SHU influences expiries and outages, it constituted  
43  
44 the model’s key performance indicator (KPI).  
45

## 46 47 **5.1. Inventory levels**

48  
49 Average daily inventory levels for the different platelet products were simulated based on  
50  
51 hospital demand variations and the results determined over five iterations to capture the  
52  
53 variability of the inputs. Simulated results were then analysed in comparison to the target  
54  
55 inventory levels held in the SHU between 1<sup>st</sup> July 2019 and 28<sup>th</sup> July 2019. Although  
56  
57 inventory holding costs are not considered in this model, holding higher inventory than  
58  
59  
60

necessary would certainly result in higher operational costs and subsequently increased wastages and shortages. The results illustrate a 14% overstock of apheresis platelets and pooled platelets, and an 82% understock of paediatric platelets (refer to *Table 2*).

Due to the uncertainty in hospital demand for the products and their lifesaving property, the SHU holds excess inventory, especially for apheresis platelets, leading to wastages. Results indicate that by using a 'pull' system where hospital demand influences the inventory levels at the SHU, performance at the SHU is improved by reducing wastages by 78% and leading to financial savings. For instance, considering the cost implications of outdated A Negative apheresis platelets, the authors determine that the organisation loses approximately £169,915 from this one product since apheresis platelets are sold to hospitals at £232.76.

>> *Insert Table 2* <<

## 5.2. Outdated units

The number of outdated units is an important KPI for blood supply chains. Since blood centres face the challenge of meeting demand without overstocking, the strategy adopted involves pushing platelets out of their system to avoid internal wastages. This is implemented by moving platelets to hospitals before they expire rather than awaiting hospital orders. Although this reduces internal wastages, it does not provide a solution to the systemic problem since wastages are only transferred to another part of the supply chain and not eliminated. This common practice was explicitly stated by Participant B who said:

*“When there is something that’s coming to end of shelf-life, they’ll push it into that local hospital.”*

While overstocking may be a safety measure, wastage of units not only affects the operational costs of the SHU but is also a waste on the donor’s time and effort (Stanger, et al., 2012). The wastage levels at the SHU when inventory is held at the units presented in *Table 2* above were analysed in comparison to the actual monthly expiries at the SHU (refer

1  
2  
3 to *Table 3*). Baesler, et al. (2014) maintains that an acceptable inventory policy is one that  
4 maximizes demand satisfaction while minimizing the levels of wastages. Adopting the ‘pull’  
5 system in determining the inventory level as opposed to utilizing fixed targets as is the  
6 current case significantly reduces the overall level of expiries from 16.63% to 3% while  
7 guaranteeing the availability of stock when hospitals demand.  
8  
9

10  
11  
12  
13  
14  
15 >> *Insert Table 3*<<

### 16 17 **5.3. Shortages**

18  
19 Shortages are not experienced when executing the model because it assumes that as soon as a  
20 replenishment order is made at the SHU, the order requests will be fulfilled by the  
21 manufacturing centre within 48 hours. In reality, this may not be possible because the  
22 collection side of the supply chain affects the availability of products at the manufacturing  
23 centre. However, considering a reasonable lead time of 48 hours and implementing the ‘pull’  
24 system the shortages are reduced from 5% to 0%.  
25  
26  
27  
28  
29  
30  
31  
32

### 33 34 **5.4. Model resilience**

35  
36 The model must be resilient to unexpected challenges and disruptions in the supply chain  
37 (Sterbenz & Smith, 2010) (such as equipment breakdown and natural disasters). Thus,  
38 resilience measures in the optimisation of inventory were taken into consideration to  
39 guarantee that hospital demand for platelet products would be met in periods of unexpected  
40 changes. The simulation model’s resilience, in this case, was tested in the event of an  
41 emergency. The average hospital demands were multiplied by a factor of 10 to determine the  
42 behaviour of the model under extreme conditions. The simulation running in virtual time  
43 mode took 3 hours 24 minutes compared to the normal conditions that took 15 minutes. The  
44 results of the simulation were compared to the baseline scenario and revealed an appropriate  
45 increase in stock levels as expected and reasonable wastages. For instance, the inventory  
46 level for A Negative apheresis platelets increased to 117 units from 12 units when the  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 demand increased from 4 to 40 units. Wastages, on the other hand, maintained at 0 units  
4  
5 indicating the sensitivity of the model to computing wastages relative to the product life span  
6  
7  
8 when there is a surge in demand.  
9

## 10 **6.0. Conclusion**

11  
12 Besides providing an innovative tool for inventory management at NHSBT, this study  
13  
14 represents the first attempt to fully understand the UK platelet supply chain. A multi-method  
15  
16 simulation model was developed to capture the activities of a real-life SHU, verified and  
17  
18 validated by experts in the UK platelet supply chain. The performance of the SHU can be  
19  
20 improved by keeping the daily inventory levels as (12A-, 34A+, 0AB-, 3AB+, 1B-, 8B+, 9O-,  
21  
22 28O+) for apheresis platelets, (7A-, 33A+, 0AB-, 1AB+, 1B-, 11B+, 7O-, 27O+) for pooled  
23  
24 platelets and ( 5A-, 1A+, 0AB-, 0AB+, 0B-, 6B+, 3O-, 1O+) for paediatric platelets while  
25  
26 strictly adhering to the FIFO policy. This paper's outcomes provide insight into the trade-off  
27  
28 between shortages and expiry rates, and can assist decision-makers in planning for optimised  
29  
30 inventory management. Additionally, incorporating measures of resilience into decision  
31  
32 making guarantees the availability of platelet products under peculiar circumstances.  
33  
34  
35  
36

37 A major limitation of this study is that operational costs were not included in the analysis.  
38  
39 Further, while the model represents the SHU operating independently from the activities at  
40  
41 the manufacturing centre and collection points, in real life, the decisions made in other parts  
42  
43 of the supply chain may significantly affect the activities at the SHU. Future research could  
44  
45 extend this model to incorporate the activities of the other parts of the supply chain to provide  
46  
47 a robust solution to the platelet problem experienced. In particular, incorporating variability  
48  
49 in supply may provide a better picture of shortages as a result of variable lead times. Future  
50  
51 research could also incorporate stock holding costs in determining the optimal stock levels to  
52  
53 illustrate the potential savings from the implementation of the optimal stock levels.  
54  
55  
56  
57

## 58 **8.0. Acknowledgements**



We express our gratitude to Professor Mike Murphy, Laura Hontoria Del Hoyo, Helen Livingstone and Jackie Morgan for their continuous support in providing data and enlightening information on the blood supply chain within the United Kingdom. Without their time and support, this project would not have been possible.

#### 9.0. Declaration of interest

The authors hold no conflict of interest with the publication of the results included in this paper.

#### 10. References

- Abdulwahab, U., & Wahab, M. I. M. (2014). Approximate dynamic programming modeling for a typical blood platelet bank. *Computers and Industrial Engineering*, 78, 259–270. <https://doi.org/10.1016/j.cie.2014.07.017>
- Baesler, F., Nemeth, M., Martínez, C., & Bastías, A. (2014). Analysis of inventory strategies for blood components in a regional blood center using process simulation. *Transfusion*, 54(2), 323–330. <https://doi.org/10.1111/trf.12287>
- Beliën, J., & Forcé, H. (2012). Supply chain management of blood products: A literature review. *European Journal of Operational Research*, 217(1), 1–16. <https://doi.org/10.1016/j.ejor.2011.05.026>
- Blake, J.T. (2009). On the use of operational research for managing platelet inventory and ordering. *Transfusion*, 49(3), 396–401.
- Blake, J. T. (2017). Determining the inventory impact of extended- shelf-life platelets with a network simulation model. *Transfusion*, 57(December), 3001–3008. <https://doi.org/10.1111/trf.14305>
- Chang, L., Yan, Y., & Wang, L. (2020). Coronavirus Disease 2019 : Coronaviruses and Blood Safety. *Transfusion Medicine Reviews*, 34(2), 75–80. <https://doi.org/10.1016/j.tmr.2020.02.003>
- Cohen, M. A., & Pierskalla, W. P. (1979). Target inventory levels for a hospital blood bank or a decentralized regional blood banking system. *Transfusion*, 19(4), 444–454. <https://doi.org/10.1046/j.1537-2995.1979.19479250182.x>
- Edwards, D.J., Rillie, I., Chileshe, N., Lai, J., Hosseini, M.R. & Thwala, W.D. (2020), "A field survey of hand–arm vibration exposure in the UK utilities sector", *Engineering, Construction and Architectural Management*, 27(9), 2179- 2198.

- 1  
2  
3 <https://doi.org/10.1108/ECAM-09-2019-0518>  
4  
5 Grigoryev, I. (2018). *Anylogic in three days: A quick course in simulation modeling*.  
6 [https://www.anylogic.com/resources/books/free-simulation-book-and-modeling-](https://www.anylogic.com/resources/books/free-simulation-book-and-modeling-tutorials/)  
7 [tutorials/](https://www.anylogic.com/resources/books/free-simulation-book-and-modeling-tutorials/).  
8  
9  
10 Haeri, A., Hosseini-Motlagh, S. M., Ghatreh Samani, M. R., & Rezaei, M. (2020). A mixed  
11 resilient-efficient approach toward blood supply chain network design. *International*  
12 *Transactions in Operational Research*, 27(4), 1962–2001.  
13  
14 <https://doi.org/10.1111/itor.12714>  
15  
16  
17 Haghjoo, N., Tavakkoli-Moghaddam, R., Shahmoradi-Moghaddam, H., & Rahimi, Y. (2020).  
18 Reliable blood supply chain network design with facility disruption: A real-world  
19 application. *Engineering Applications of Artificial Intelligence*, 90(April 2019), 103493.  
20  
21 <https://doi.org/10.1016/j.engappai.2020.103493>  
22  
23  
24 Haijema, R., van Dijk, N., van der Wal, J., & Smit S. C. (2009). Blood platelet production  
25 with breaks: optimization by SDP and simulation. *International Journal of Production*  
26 *Economics*, 121(2), 464–473. <https://doi.org/10.1016/j.ijpe.2006.11.026>  
27  
28  
29 Hamdan, B., & Diabat, A. (2020). Robust design of blood supply chains under risk of  
30 disruptions using Lagrangian relaxation. *Transportation Research Part E: Logistics and*  
31 *Transportation Review*, 134(August 2019), 101764.  
32  
33 <https://doi.org/10.1016/j.tre.2019.08.005>  
34  
35  
36 Harrell, C.R., Bateman, R.E. & Gogg, T.J. (1995). *System improvement using simulation* (3rd  
37 ed.). Orem (UT): PROMODEL® Corporation.  
38  
39  
40 Hosseini-Motlagh, S. M., Samani, M. R. G., & Homaei, S. (2020). Toward a coordination of  
41 inventory and distribution schedules for blood in disasters. *Socio-Economic Planning*  
42 *Sciences*, December 2019, 100897. <https://doi.org/10.1016/j.seps.2020.100897>  
43  
44  
45 Katsaliaki, K., & Brailsford, S. C. (2017). *Using simulation to improve the blood supply*  
46 *chain Using simulation to improve the blood supply chain*. 5682.  
47  
48 <https://doi.org/10.1057/palgrave.jors.2602195>  
49  
50  
51 Lu, N. Z. and X. (2009). Comparative study on push and pull production system based on  
52 Anylogic. *International Conference on Electronic Commerce and Business Intelligence*,  
53 455–458. <https://doi.org/10.1109/ECBI.2009.26>  
54  
55  
56 Osorio, A. F., Brailsford, S. C., & Smith, H. K. (2015). A structured review of quantitative  
57 models in the blood supply chain: A taxonomic framework for decision-making.  
58 *International Journal of Production Research*, 53(24), 7191–7212.  
59  
60 <https://doi.org/10.1080/00207543.2015.1005766>

- 1  
2  
3 Pärn, E. A. and Edwards, D. J. (2017) Conceptualising the FINDD API plug-in: a study of  
4 BIM-FM integration. *Automation in Construction*, 80, pp. 11-21.  
5  
6 DOI:10.1016/j.autcon.2017.03.015  
7  
8 Rajendran, S., & Ravindran, R. A. (2020). Multi-criteria approach for platelet inventory  
9 management in hospitals. *International Journal of Operational Research*, 38(1), 49–69.  
10  
11 <https://doi.org/10.1504/IJOR.2020.106360>  
12  
13 Rajendran, S., & Srinivas, S. (2020). Hybrid ordering policies for platelet inventory  
14 management under demand uncertainty. *IISE Transactions on Healthcare Systems*  
15 *Engineering*, 10(2), 113–126. <https://doi.org/10.1080/24725579.2019.1686718>  
16  
17 Roberts, C. J., Pärn, E. A., Edwards, D. J. and Aigbavboa, C. (2018) Digitalising asset  
18 management: concomitant benefits and persistent challenges. *International Journal of*  
19 *Building Pathology and Adaptation*, 36(2), pp. 152-173. DOI:10.1108/IJBPA-09-2017-  
20 0036  
21  
22 Samani, M. R. G., Hosseini-Motlagh, S. M., & Homaei, S. (2020). A reactive phase against  
23 disruptions for designing a proactive platelet supply network. *Transportation Research*  
24 *Part E: Logistics and Transportation Review*, 140(May), 102008.  
25  
26 <https://doi.org/10.1016/j.tre.2020.102008>  
27  
28 Stanger, S. H. W., Wilding, R., Yates, N., & Cotton, S. (2012). What drives perishable  
29 inventory management performance? Lessons learnt from the UK blood supply chain.  
30 *Supply Chain Management: An International Journal*, 17(2), 107–123.  
31  
32 <https://doi.org/10.1108/13598541211212861>  
33  
34 Sterbenz, J.P.G., Smith, P. (2010). Resilience and survivability in communication networks:  
35 Strategies, principles and survey of disciplines. *Computer Networks*, 54(8), 1245–1265.  
36  
37 <https://doi.org/https://doi.org/10.1016/j.comnet.2010.03.005>  
38  
39 Terzi, S., & Cavalieri, S. (2004). *Simulation in the supply chain context : a survey*. 53, 3–16.  
40  
41 [https://doi.org/10.1016/S0166-3615\(03\)00104-0](https://doi.org/10.1016/S0166-3615(03)00104-0)  
42  
43 Van Dijk, N., Haijema, R., Van Der Wal, J., & Sibinga, C. S. (2009). Blood platelet  
44 production: A novel approach for practical optimization. *Transfusion*, 49(3), 411–420.  
45  
46 <https://doi.org/10.1111/j.1537-2995.2008.01996.x>  
47  
48 World Health Organization. (2011). *Maintaining a safe and adequate blood supply during*  
49 *pandemic influenza: Guidelines for Blood Transfusion Services*.  
50  
51 [https://www.who.int/bloodsafety/publications/WHO\\_Guidelines\\_on\\_Pandemic\\_Influenza\\_and\\_Blood\\_Supply.pdf](https://www.who.int/bloodsafety/publications/WHO_Guidelines_on_Pandemic_Influenza_and_Blood_Supply.pdf)  
52  
53  
54  
55  
56  
57  
58  
59  
60 Yaghoubi, S., Hosseini-Motlagh, S. M., Cheraghi, S., & Gilani Larimi, N. (2020). Designing

1  
2  
3 a robust demand-differentiated platelet supply chain network under disruption and  
4 uncertainty. *Journal of Ambient Intelligence and Humanized Computing*, 11(8), 3231–  
5 3258. <https://doi.org/10.1007/s12652-019-01501-0>  
6  
7

8 Zahiri, B., Torabi, S. A., Mohammadi, M., & Aghabegloo, M. (2018). A multi-stage  
9 stochastic programming approach for blood supply chain planning. *Computers and*  
10 *Industrial Engineering*, 122(February 2017), 1–14.  
11  
12 <https://doi.org/10.1016/j.cie.2018.05.041>  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For Peer Review Only

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**List of figures**

Figure 1: Overview of the research process .....7

Figure 2: Model pull logic.....8

Figure 3: Model behaviour flowchart .....9

For Peer Review Only




Figure 1: Overview of the research process (Source: Authors)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60




Figure 2: Model pull logic (Source: Authors)




Figure 3: Model behaviour flowchart (Source: Authors)



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**List of tables**

Table 1: Model validation- Comparison of actual data to simulation results .....11

Table 2: Simulation Results for Daily Inventory Levels .....12

Table 3: Analysis of SHU outdated (expired) units .....13

For Peer Review Only

**Table 1: Model validation- Comparison of actual data to simulation results**

| <b>Apheresis platelets</b> |                        |                 |                        |                 |                        |                 |
|----------------------------|------------------------|-----------------|------------------------|-----------------|------------------------|-----------------|
|                            | <b>Actual</b>          |                 | <b>Simulated</b>       |                 | <b>Variances</b>       |                 |
| <b>Blood type</b>          | <b>Inventory level</b> | <b>Wastages</b> | <b>Inventory level</b> | <b>Wastages</b> | <b>Inventory level</b> | <b>Wastages</b> |
| <b>A-</b>                  | 14                     | 5               | 13                     | 3               | 1                      | 2               |
| <b>A+</b>                  | 35                     | 14              | 34                     | 12              | 1                      | 2               |
| <b>AB-</b>                 | 1                      | 0               | 1                      | 0               | 0                      | 0               |
| <b>AB+</b>                 | 3                      | 1               | 3                      | 0               | 0                      | 1               |
| <b>B-</b>                  | 2                      | 1               | 1                      | 0               | 1                      | 1               |
| <b>B+</b>                  | 10                     | 5               | 9                      | 5               | 1                      | 0               |
| <b>O-</b>                  | 5                      | 2               | 7                      | 1               | 2                      | 1               |
| <b>O+</b>                  | 26                     | 10              | 27                     | 9               | 1                      | 1               |

**Table 2: Simulation Results for Daily Inventory Levels**

| Blood type | Apheresis     |               |                    | Pooled        |               |                   | Paedi         |               |                   |
|------------|---------------|---------------|--------------------|---------------|---------------|-------------------|---------------|---------------|-------------------|
|            | Model results | Actual target | % over/under stock | Model results | Actual target | %over/under stock | Model results | Actual target | %over/under stock |
| <b>A-</b>  | 12            | 14            | 14% overstock      | 7             | 12            | 42% overstock     | 5             | 1             | 400% understock   |
| <b>A+</b>  | 34            | 35            | 3% overstock       | 33            | 30            | 10% understock    | 1             | 4             | 75% overstock     |
| <b>AB-</b> | -             | 1             | 100% overstock     | -             | 1             | 100% overstock    | 0             | 1             | 100% overstock    |
| <b>AB+</b> | 3             | 3             | 0%                 | 1             | 2             | 50% overstock     | 0             | 1             | 100% overstock    |
| <b>B-</b>  | 1             | 2             | 50% overstock      | 1             | 2             | 50% overstock     | 0             | 1             | 100% overstock    |
| <b>B+</b>  | 8             | 10            | 20% overstock      | 11            | 9             | 22% understock    | 6             | 1             | 500% understock   |
| <b>O-</b>  | 9             | 5             | 80% understock     | 7             | 4             | 75% understock    | 3             | 1             | 200% understock   |
| <b>O+</b>  | 28            | 26            | 8% understock      | 27            | 22            | 23% understock    | 1             | 3             | 67% overstock     |

**Table 3: Analysis of SHU outdated (expired) units**

| Blood type | Apheresis    |                 |               | Pooled       |                 |               | Paedi        |                 |               |
|------------|--------------|-----------------|---------------|--------------|-----------------|---------------|--------------|-----------------|---------------|
|            | Actual units | Simulated units | % improvement | Actual units | Simulated units | % improvement | Actual units | Simulated units | % improvement |
| A-         | 5            | 0               | 100%          | 6            | -               | 100%          | 5            | 0               | 100%          |
| A+         | 14           | 4               | 71%           | 16           | 4               | 75%           | 13           | 0               | 100%          |
| AB-        | 0            | 0               | 0%            | 0            | 0               | 0%            | 0            | 0               | 0%            |
| AB+        | 1            | 0               | 100%          | 1            | -               | 100%          | 2            | 0               | 100%          |
| B-         | 1            | 0               | 100%          | 1            | -               | 100%          | 1            | 0               | 100%          |
| B+         | 5            | 1               | 78%           | 5            | 1               | 81%           | 6            | 1               | 83%           |
| O-         | 2            | 1               | 56%           | 3            | -               | 100%          | 3            | 0               | 100%          |
| O+         | 10           | 4               | 61%           | 12           | 3               | 75%           | 14           | 0               | 100%          |